Home
/
Conditions
/ Hyperparathyroidism
Musculoskeletal and Endocrine Health
Schedule a Consultation
Hyperparathyroidism
Hyperparathyroidism is a condition in which one or more parathyroid glands produce excess parathyroid hormone (PTH), disrupting calcium homeostasis and producing a cascade of consequences across bone, kidney, cardiovascular, and neurological systems. Primary hyperparathyroidism, caused by a parathyroid adenoma or hyperplasia, is the most common form and is frequently discovered incidentally on routine bloodwork as elevated calcium. Secondary hyperparathyroidism, driven by vitamin D deficiency or chronic kidney disease, is even more prevalent but less commonly identified. At The Lamkin Clinic, we evaluate the full calcium-PTH-vitamin D axis and identify the specific mechanism driving the parathyroid dysfunction.
Endocrine HealthCalcium MetabolismTreatable
1 in 500adults has primary hyperparathyroidism
Bone Losselevated PTH directly increases osteoclast activity and bone resorption
Identifiablewith calcium, PTH, and vitamin D evaluation together
← Back to Conditions
Condition: Hyperparathyroidism | Category: Musculoskeletal and Endocrine Health | Reviewed by: Brian Lamkin, DO
What Is Hyperparathyroidism?
Hyperparathyroidism is a disorder of calcium regulation in which one or more of the four parathyroid glands produce excess parathyroid hormone (PTH). PTH is the primary regulator of calcium homeostasis: it increases blood calcium by stimulating osteoclast-mediated bone resorption, increasing renal calcium reabsorption, and stimulating renal production of active vitamin D (1,25-dihydroxyvitamin D) to enhance intestinal calcium absorption. When PTH production is elevated beyond physiological need, this regulatory system becomes destructive.
Primary hyperparathyroidism, the most common form, results from a parathyroid adenoma (approximately 85 percent of cases), four-gland hyperplasia (approximately 15 percent), or rarely, parathyroid carcinoma. It produces elevated calcium with inappropriately normal or elevated PTH. Secondary hyperparathyroidism is a compensatory response to chronically low calcium or low vitamin D: the parathyroid glands increase PTH production to maintain blood calcium from bone stores. Calcium is normal or low while PTH is elevated. The distinction between primary and secondary determines the treatment approach entirely.
Key principle: Calcium and PTH must always be interpreted together. Elevated calcium with elevated PTH is primary hyperparathyroidism (gland problem). Normal or low calcium with elevated PTH is secondary hyperparathyroidism (usually vitamin D deficiency). Elevated calcium with suppressed PTH is not hyperparathyroidism at all; it is a different diagnostic pathway (malignancy, granulomatous disease, or excessive supplementation). The three-value triad of calcium, PTH, and vitamin D is the minimum evaluation required.
Why Hyperparathyroidism Matters
Clinical Consequences
- Accelerated bone loss: elevated PTH directly increases osteoclast activity, producing osteoporosis and increased fracture risk, particularly at cortical bone sites (distal radius, femoral neck)
- Kidney stones: hypercalciuria from elevated filtered calcium load; calcium oxalate and calcium phosphate stones are the most common presentation leading to primary hyperparathyroidism diagnosis
- Cardiovascular risk: chronic hypercalcemia is associated with hypertension, left ventricular hypertrophy, vascular calcification, and increased cardiovascular mortality
- Neuropsychiatric symptoms: fatigue, depression, cognitive difficulty, and anxiety from calcium-mediated neurological disruption are present in the majority of patients but frequently attributed to other causes
Why This Condition Is Undertreated
- "Mild" hypercalcemia is monitored rather than treated: primary hyperparathyroidism with calcium 10.3 to 10.8 mg/dL is classified as "mild" and followed with watchful waiting despite producing progressive bone loss and neuropsychiatric symptoms
- PTH is not measured with calcium: elevated calcium on a basic metabolic panel frequently triggers repeat testing without concurrent PTH measurement, delaying diagnosis by months or years
- Secondary hyperparathyroidism from vitamin D deficiency is extremely common but not systematically screened for; patients with osteoporosis are treated with bisphosphonates without evaluating the PTH-vitamin D axis driving the bone loss
- Nonspecific symptoms are attributed to other diagnoses: the fatigue, brain fog, depression, and muscle weakness of hyperparathyroidism are commonly attributed to aging, depression, or fibromyalgia rather than investigated as calcium-mediated dysfunction
Common Symptoms
Classical (Stones, Bones, Groans, Moans)
- Kidney stones (calcium oxalate or phosphate)
- Bone pain and declining bone density
- Constipation and abdominal discomfort
- Depression, anxiety, and cognitive difficulty
Nonspecific (Most Common Presentation)
- Fatigue and low energy
- Brain fog and difficulty concentrating
- Muscle weakness and generalized aching
- Sleep disruption
Metabolic
- Excessive thirst and frequent urination
- Elevated blood pressure
- Nausea and reduced appetite (severe cases)
- Incidental finding of elevated calcium on routine labs
Root Causes: A Functional Medicine Perspective
Conventional endocrinology diagnoses hyperparathyroidism and monitors or refers for surgery. Functional medicine evaluates the full calcium-PTH-vitamin D axis and the metabolic context in which the parathyroid dysfunction is occurring.
Primary Hyperparathyroidism
A parathyroid adenoma (a benign tumor of one gland) produces PTH autonomously, independent of calcium feedback. This raises blood calcium progressively while depleting bone. The diagnosis is confirmed by simultaneous elevation of calcium and PTH, with normal or elevated 24-hour urine calcium (distinguishing it from familial hypocalciuric hypercalcemia, which has low urine calcium). Parathyroidectomy has a cure rate exceeding 95 percent and is the definitive treatment.
Secondary Hyperparathyroidism from Vitamin D Deficiency
Vitamin D deficiency is the most common cause of elevated PTH in clinical practice. When vitamin D is insufficient (below 30 ng/mL, and particularly below 20 ng/mL), intestinal calcium absorption decreases, and the parathyroid glands respond by increasing PTH to maintain blood calcium through bone resorption. This compensatory PTH elevation produces progressive bone loss that is entirely preventable through vitamin D repletion. Functional medicine targets vitamin D at 60 to 80 ng/mL, substantially above the conventional threshold of 30 ng/mL.
Magnesium Deficiency and PTH Regulation
Magnesium is required for PTH secretion, PTH receptor sensitivity, and the conversion of vitamin D to its active form. Magnesium deficiency can produce a paradoxical state of low PTH with low calcium (hypoparathyroidism) or, more commonly, impair the vitamin D-PTH feedback loop such that PTH remains inappropriately elevated. Magnesium status must be assessed in any patient with calcium-PTH dysregulation.
Chronic Kidney Disease and Vitamin D Activation
The kidneys convert inactive 25-hydroxyvitamin D to active 1,25-dihydroxyvitamin D (calcitriol) through the enzyme 1-alpha-hydroxylase. In chronic kidney disease, this conversion is impaired, reducing active vitamin D and calcium absorption regardless of 25-hydroxyvitamin D levels. PTH rises compensatorily, producing the secondary hyperparathyroidism of renal disease. Renal function assessment (GFR, creatinine) is a required component of hyperparathyroidism evaluation.
Conventional vs Functional Medicine Approach
| Domain | Conventional Medicine | Functional Medicine |
|---|---|---|
| Diagnosis | Calcium + PTH; vitamin D sometimes checked; monitoring for mild primary | Calcium, PTH, vitamin D (25-OH), RBC magnesium, 24-hour urine calcium, renal function, bone density evaluated as integrated axis |
| Primary treatment | Surgery if criteria met; monitoring if mild | Surgery referral when indicated; comprehensive bone health optimization with vitamin D, magnesium, K2, and lifestyle intervention pre and post-operatively |
| Secondary treatment | Vitamin D supplementation to 30 ng/mL minimum | Vitamin D optimization to 60 to 80 ng/mL with magnesium cofactor support and serial PTH monitoring to confirm normalization |
| Bone health | Bisphosphonates for osteoporosis | Resolve the PTH driver (surgery or vitamin D), optimize vitamin D, K2, magnesium, and resistance training before considering anti-resorptive medication |
Key Labs to Evaluate
Hyperparathyroidism evaluation requires the calcium-PTH-vitamin D triad at minimum, with additional markers to determine the type and metabolic context.
Vitamin DLow vitamin D is the most common cause of secondary hyperparathyroidism. Target 60 to 80 ng/mL.
→RBC MagnesiumMagnesium cofactor for PTH regulation and vitamin D activation.
→hs-CRPInflammatory burden. Chronic inflammation compounds bone loss from PTH elevation.
→TSHThyroid dysfunction coexists with parathyroid disorders and independently affects bone density.
→CortisolExcess cortisol accelerates bone resorption independently of PTH status.
→How to Interpret These Labs Together
Calcium 10.6 with PTH 85 pg/mL and vitamin D 24 ng/mL requires careful interpretation. The elevated calcium with elevated PTH suggests primary hyperparathyroidism, but the low vitamin D means that vitamin D deficiency may be contributing a secondary component. The correct approach: replete vitamin D to 60 to 80 ng/mL and recheck calcium and PTH. If calcium normalizes and PTH declines, it was predominantly secondary. If calcium remains elevated with inappropriately elevated PTH despite adequate vitamin D, primary hyperparathyroidism is confirmed.
Calcium 9.4 with PTH 92 pg/mL and vitamin D 16 ng/mL is classic secondary hyperparathyroidism: the calcium is normal (maintained by elevated PTH pulling calcium from bone), PTH is elevated (compensating for low vitamin D), and the bone loss is ongoing despite normal calcium. Vitamin D repletion to 60 to 80 ng/mL with magnesium cofactor support will normalize PTH and stop the compensatory bone resorption.
Calcium 11.2 with PTH 120 pg/mL and vitamin D 42 ng/mL confirms primary hyperparathyroidism: calcium is significantly elevated, PTH is markedly elevated despite adequate vitamin D (removing secondary contribution), and parathyroidectomy referral is indicated.
Common Patterns Seen in Patients
- The patient with osteoporosis on bisphosphonates without PTH evaluation: Bone density declining despite 3 years of alendronate. PTH never measured. PTH 78, vitamin D 19. Secondary hyperparathyroidism from vitamin D deficiency producing the bone loss. The bisphosphonate was suppressing the remodeling response while the PTH-driven resorption continued because the vitamin D deficiency driving PTH elevation was never addressed. Vitamin D repletion normalized PTH and improved bone density trajectory.
- The patient with "borderline" high calcium told to recheck in 6 months: Calcium 10.4 on routine labs. Repeated at 10.5 three months later. PTH not measured either time. On the third draw, PTH was finally checked: 72 pg/mL (inappropriately elevated for the calcium). Two years of progressive bone loss and neuropsychiatric symptoms occurred during the monitoring period. PTH should be measured with the first elevated calcium, not months later.
- The patient with fatigue and brain fog attributed to depression: Two-year history of progressive fatigue, cognitive difficulty, low mood, and muscle weakness. Treated with SSRI and told to exercise more. Calcium 10.7, PTH 88. Primary hyperparathyroidism producing the classic neuropsychiatric presentation. Parathyroidectomy resolved the fatigue, cognitive dysfunction, and mood symptoms within 2 months.
- The kidney stone patient without endocrine evaluation: Third calcium oxalate kidney stone. Advised to drink more water and reduce oxalate. No calcium or PTH evaluation. Calcium 10.9, PTH 94. Primary hyperparathyroidism producing the hypercalciuria driving recurrent stone formation. Parathyroidectomy eliminated the metabolic driver; no further stones in 3 years.
Treatment and Optimization Strategy
Type-Specific Intervention
Treatment is entirely determined by whether the hyperparathyroidism is primary (gland problem requiring surgical evaluation) or secondary (vitamin D/calcium deficiency requiring repletion).
Primary Hyperparathyroidism
- Surgical referral for parathyroidectomy when criteria are met: calcium >1 mg/dL above normal, T-score below -2.5, kidney stones, age under 50, or significant symptoms
- Pre-operative vitamin D optimization to prevent hungry bone syndrome post-operatively
- Bone density assessment (DEXA) at diagnosis and post-operatively to document improvement
- Post-operative calcium and PTH monitoring to confirm cure and detect the rare multi-gland disease
Secondary Hyperparathyroidism
- Vitamin D repletion to 60 to 80 ng/mL using vitamin D3 with serial 25-OH vitamin D and PTH monitoring
- Magnesium glycinate (400mg daily) as cofactor for vitamin D activation and PTH receptor function
- Vitamin K2 (MK-7, 200mcg daily) to direct calcium into bone rather than soft tissue
- Resistance training for mechanical loading stimulus to osteoblast activity alongside the hormonal correction
What Most Doctors Miss
- PTH is not measured with elevated calcium: the most common diagnostic failure. Elevated calcium on a basic metabolic panel is repeated without concurrent PTH, delaying diagnosis by months or years while bone loss, kidney stones, and neuropsychiatric symptoms progress.
- Secondary hyperparathyroidism from vitamin D deficiency is not screened for: the most common cause of elevated PTH in clinical practice is vitamin D insufficiency, yet routine screening for the vitamin D-PTH axis is not standard practice
- "Mild" primary hyperparathyroidism is undertreated: calcium levels of 10.3 to 10.8 are monitored annually rather than treated, despite producing measurable bone loss and significant quality-of-life impairment from neuropsychiatric symptoms. Parathyroidectomy has a 95 percent cure rate with minimal morbidity.
- Magnesium is not assessed: magnesium is required for PTH secretion, PTH receptor sensitivity, and vitamin D activation. Magnesium deficiency impairs every aspect of calcium-PTH regulation and is not part of standard evaluation.
When to Seek Medical Care
If routine bloodwork reveals elevated calcium, if you have recurrent kidney stones, unexplained bone loss, or if you experience progressive fatigue, brain fog, muscle weakness, or depression without a clear cause, evaluation of the calcium-PTH-vitamin D axis is warranted. This is especially important if you have been told your elevated calcium is "borderline" and should simply be monitored.
At The Lamkin Clinic, hyperparathyroidism evaluation includes serum calcium, intact PTH, 25-hydroxyvitamin D, RBC magnesium, 24-hour urine calcium, renal function, bone density, and comprehensive metabolic assessment.
Recommended Testing
Hyperparathyroidism evaluation requires the calcium-PTH-vitamin D triad at minimum, with additional markers to determine type and metabolic context.
Calcium-PTH Axis
- Serum Calcium (ionized if available)
- Intact PTH
- 25-Hydroxyvitamin D
- 24-Hour Urine Calcium
Metabolic Context
- RBC Magnesium
- Phosphorus
- Creatinine / GFR
- Alkaline Phosphatase
- DEXA Bone Density
Need guidance on parathyroid evaluation?
Schedule a Consultation →Frequently Asked Questions
What is the difference between primary and secondary hyperparathyroidism?
Primary is caused by a parathyroid gland abnormality producing PTH autonomously. Calcium is elevated and PTH is inappropriately elevated. Secondary is a compensatory response to low calcium or low vitamin D. Calcium is normal or low while PTH is elevated. The distinction determines treatment: primary often requires surgery; secondary requires vitamin D repletion.
Can hyperparathyroidism cause osteoporosis?
Yes. Elevated PTH directly increases osteoclast activity, accelerating bone resorption, particularly at cortical bone sites. Patients with hyperparathyroidism have significantly elevated fracture risk. Successful treatment (surgery for primary, vitamin D for secondary) can produce measurable bone density improvement.
What are the symptoms of hyperparathyroidism?
The classic presentation includes kidney stones, bone pain, constipation, and depression. However, many patients present with nonspecific symptoms: fatigue, brain fog, muscle weakness, and low mood that are attributed to other causes. These neuropsychiatric symptoms frequently resolve after parathyroidectomy.
Is vitamin D deficiency related to hyperparathyroidism?
Yes. Vitamin D deficiency is the most common cause of secondary hyperparathyroidism. When vitamin D is insufficient, calcium absorption decreases and parathyroid glands increase PTH to maintain blood calcium from bone. Vitamin D repletion to optimal levels typically normalizes PTH in secondary hyperparathyroidism.
When does hyperparathyroidism require surgery?
Parathyroidectomy is recommended for primary hyperparathyroidism with calcium more than 1 mg/dL above normal, T-score below -2.5, kidney stones, reduced kidney function, or age under 50. Many surgeons also recommend surgery for symptomatic patients not meeting these thresholds. The cure rate exceeds 95 percent.
How The Lamkin Clinic Approaches Hyperparathyroidism
Clinical Perspective
The most common parathyroid finding I encounter is not primary hyperparathyroidism from an adenoma. It is secondary hyperparathyroidism from vitamin D deficiency that has been producing silent bone loss for years while the patient's calcium appeared normal and no one checked PTH. The calcium looks fine because the elevated PTH is maintaining it by pulling calcium from bone. The bone density scan tells the real story. The fix is straightforward: replete the vitamin D, normalize the PTH, and the bone resorption stops. For primary hyperparathyroidism, parathyroidectomy is one of the most gratifying surgeries in medicine because the patients feel better within days to weeks of removing the adenoma.
Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma
At The Lamkin Clinic, hyperparathyroidism evaluation includes the complete calcium-PTH-vitamin D axis, RBC magnesium, renal function, 24-hour urine calcium, and bone density assessment. Treatment is type-specific: surgical referral for confirmed primary hyperparathyroidism, and vitamin D optimization with magnesium cofactor support and serial PTH monitoring for secondary hyperparathyroidism.
Related Conditions
OsteoporosisPTH-driven bone resorption as a primary cause of bone density decline
→Thyroid DysfunctionThyroid and parathyroid disorders coexist and independently affect bone health
→Nutrient DeficienciesVitamin D and magnesium deficiency as primary drivers of secondary hyperparathyroidism
→Chronic InflammationInflammation compounding PTH-driven bone loss through cytokine-mediated osteoclast activation
→Chronic FatigueCalcium-mediated neurological dysfunction producing disabling fatigue
→Cognitive DeclineHypercalcemia-driven cognitive impairment that resolves with PTH normalization
→Related Symptoms
Chronic FatigueCalcium-mediated neuromuscular dysfunction producing persistent low energy
→Brain FogHypercalcemia impairing cognitive processing and concentration
→Depression BiologyCalcium-mediated neuropsychiatric disruption producing depressive symptoms
→Sleep DisturbanceHypercalcemia and musculoskeletal discomfort disrupting sleep architecture
→Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.
Calcium and PTH must always be interpreted together. The triad of calcium, PTH, and vitamin D is the minimum evaluation.
The Lamkin Clinic evaluates hyperparathyroidism with the complete calcium-PTH-vitamin D axis, magnesium, bone density, and comprehensive metabolic assessment. Schedule a consultation for parathyroid and bone health evaluation.
Schedule a ConsultationMedical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.